Show simple item record

dc.contributor.authorGray, Richard
dc.contributor.authorPatel, Smitaa
dc.contributor.authorIves, Natalie
dc.contributor.authorRick, Caroline
dc.contributor.authorWoolley, Rebecca
dc.contributor.authorMuzerengi, Sharon
dc.contributor.authorGray, Alastair
dc.contributor.authorJenkinson, Crispin
dc.contributor.authorMcIntosh, Emma
dc.contributor.authorWheatley, Keith
dc.contributor.authorWilliams, Adrian
dc.contributor.authorClarke, C. E.
dc.contributor.authorPD MED Collaborative Group
dc.date.accessioned2022-07-06T09:54:02Z
dc.date.available2022-07-06T09:54:02Z
dc.date.issued2021-12-28
dc.identifier.citationGray , R , Patel , S , Ives , N , Rick , C , Woolley , R , Muzerengi , S , Gray , A , Jenkinson , C , McIntosh , E , Wheatley , K , Williams , A , Clarke , C E & PD MED Collaborative Group 2021 , ' Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy : The PD MED Randomized Clinical Trial ' , JAMA Neurology , vol. 79 , no. 2 , pp. 131-140 . https://doi.org/10.1001/jamaneurol.2021.4736en
dc.identifier.issn2168-6149
dc.identifier.otherPURE: 211980931
dc.identifier.otherPURE UUID: 516d148c-b010-4312-9176-91e068cefa6c
dc.identifier.otherBibtex: 10.1001/jamaneurol.2021.4736
dc.identifier.otherScopus: 85122131087
dc.identifier.urihttps://hdl.handle.net/2164/18799
dc.descriptionFunding/Support: The PD MED clinical trial was supported by funding from the Health Technology Assessment Programme of the UK National Institute for Health Research (project number 98/03/02), the UK Department of Health through March 2012 (University of Birmingham Clinical Trials Unit, supporting the salaries of Mss Ives and Patel), the UK Medical Research Council (Mr R. Gray), and Parkinson’s UK (Dr McIntosh). We thank all of the patients who agreed to enter the study, the many investigators who also contributed to the clinical trial, and NHS Digital, which provided data on mortality and data from the Hospital Episodes Statistics database. The investigators received no payment or other compensation for taking part in the PD MED clinical trial.en
dc.format.extent19
dc.language.isoeng
dc.relation.ispartofJAMA Neurologyen
dc.rightsThis is an open access article distributed under the terms of the CC-BY license, which permits unrestricted use, distribution, and reproduction in any medium. You are not required to obtain permission to reuse this article content, provided that you credit the author and journal. If you are the author of this article and have questions about the Creative Commons license, please contact permissions@jamanetwork.com.en
dc.subjectR Medicineen
dc.subjectSupplementary Dataen
dc.subjectSupplementary Informationen
dc.subject.lccRen
dc.titleLong-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy : The PD MED Randomized Clinical Trialen
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen.Data Safe Havenen
dc.contributor.institutionUniversity of Aberdeen.Chronic Disease Research Groupen
dc.contributor.institutionUniversity of Aberdeen.Other Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Institute of Applied Health Sciencesen
dc.description.statusPeer revieweden
dc.description.versionPublisher PDFen
dc.identifier.doihttps://doi.org/10.1001/jamaneurol.2021.4736


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record